Pharma DECODED
Latest edition: 14 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
Sanofi to make €1bn biomanufacturing investment in France
The investment will create more than 500 jobs and enhance medicine production capabilities in the region.
Latest news
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Fulcrum entered an exclusive global license deal with GSK for rights to the oral small-molecule drug losmapimod in April 2019.
UK Government expands opioid overdose treatment access
Naloxone is known for its rapid action in reversing opioid overdose effects, particularly breathing difficulties.
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Regeneron and Sanofi’s injection saw sales of $11.59bn in 2023 as it gets a step closer to another indication.
OCT Europe: Interpreting CTR remains a pain point for sponsors
While an improvement over the previous iteration, the EU Clinical Trials Regulation (CTR) still presents problems for sponsors.
Novo Nordisk shares positive results from Phase IIIa trial of haemophilia A drug
A statistically significant decline in treated bleeding episodes with weekly and monthly doses of Mim8 was reported in the trial.
AI database to bolster research for GLP1-RAs as precision medicines
Dandelion Health’s AI database can be used as a tool for sponsors to decide which indications to next investigate GLP1-RAs in.
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
The company aims to finish enrolling subjects in the trial before the end of this year.
In our previous edition
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Pharma Decoded
Takeda tackles $900m restructuring plan after generics hurt annual profits
10 May 2024
Pharma Decoded
ESCMID 2024: Emerging bacterial infections in neonates and children
09 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer